Vnitr Lek 2015, 61(11):953-957
Evolocumab and PROFICIO Project: Initial Results
- II. interní klinika 3. LF UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Michal Anděl, CSc.
The PROFICIO project includes 20 clinical studies evaluating the effect of evolocumab on the incidence of cardiovascular disease including its safety profile and tolerance. Most of the included studies follow the average proportional decrease of LDL-cholesterol concentrations over 10 and 12 weeks of administering evolocumab as compared to the input values. The first results were announced at the congress of the European Society of Cardiology (ESC) in London at the end of August and beginning of September 2015. This subanalysis comprised 3146 patients, who underwent one of the selected studies of phase 3 clinical testing and who were administered a dose of 140 mg s.c. evolocumab once in 2 weeks, or 420 mg s.c. once in 4 weeks. LDL-cholesterol levels decreased after evolocumab by 56.5 - 74.9% in the individual studies as compared to placebo and by 36.9 - 44.9% compared to ezetimib. The incidence of adverse effects did not differ from the group which used placebo.
Keywords: evolocumab; PROFICIO project; LDL-cholesterol; cardiovascular risk
Received: November 1, 2015; Accepted: November 23, 2015; Published: November 1, 2015 Show citation
References
- ESC/EAS Guidelines for the management of dyslipidemias. European Heart Journal 2011; 32(14): 1769-1818.
- Stroes E, Robinson J, Raal F et al. Clinical equivalence of evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 Studies. European Society of Cardiology 29.8.-2.9. 2015. London. Abstract P1756, Poster Presentation.
Go to original source... - Koren MJ, Lundquist P, Bolognese M et al. Anti-PCSK-9 Monotherapy for Hypercholesterolemia. The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab. JACC 2014; 63(23): 2531-2540. Go to original source...
Go to PubMed... - Robinson JG, Nedergaard BS, Rogers WJ et al. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. The LAPLACE-2 Randomized Clinical Trial. JAMA 2014; 311(18): 1870-1882. Go to original source... Go to PubMed...
- Stroes E, Calquhoun D, Sullivan D et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63(23): 2541-2548. Go to original source... Go to PubMed...
- Raal FJ, Honarpour N, Blom DJ et al. Inhibition of PCSK9 With Evolocumab in Homozygous Familial Hypercholesterolemie (TESLA Part B): A Randomise Double-Blind, Placebo-Controlled Trial. Lancet 2015; 385(9965): 341-350. Go to original source... Go to PubMed...